After 6 months, placebo was associated with a mean weight gain of 0.4 kg (o.88 lb), compared with 1.2-1.9 kg (2.6-4.2 lb) ...

Tirzepatide (Zepbound) came out on top against semaglutide (Wegovy) for treating obesity in the head-to-head SURMOUNT-5 trial ...

Although the immediate market response was negative, most pharmaceutical stocks recovered after Wall Street analysts ...

But when a dividend yield reaches ultrahigh levels, investors can feel a heightened level of uncertainty. Wondering if Pfizer ...

We recently published a list of Domestic Manufacturing Boom: 12 Best Pharma Stocks to Invest in Now. In this article, we are ...

Pfizer (NYSE:PFE) is one of the world’s largest pharmaceutical companies, but at $22.59 per share as of this writing, the ...

A combination of the HER2 agent, called disitamab vedotin, and Junshi Biosciences’ PD-1 inhibitor toripalimab outperformed ...

With biotech stocks broadly having a strong run in 2025, and with more of the year ahead, investors are still looking for ...

There are significant questions on how the order can be implemented, and if companies can raise prices on already approved ...

Tirzepatide conferred significantly greater weight loss than semaglutide at 72 weeks for adults with overweight or obesity, ...

We recently published a list of 11 Best Performing Healthcare Stocks to Buy Now. In this article, we are going to take a look ...

President Donald Trump on Monday signed a sweeping executive order setting a 30-day deadline for drugmakers to electively ...